• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis accelerates work on inflammatory biomarkers associated with COVID-19
Share
Announcements, News

ProAxsis accelerates work on inflammatory biomarkers associated with COVID-19

August 3, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded an Innovate UK grant as part of the “business-led innovation in response to global disruption” scheme, which was set up in light of the COVID-19 pandemic.  The £50,000 award will be utilised to develop novel sputum-based cytokine multiplex assays.

Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:

 “A number of cytokines have been associated with COVID-19 infection so we anticipate an increased future need for extensive testing of these proteins in a range of biological fluids, both for monitoring people infected with the COVID-19 virus, and also to support the development of novel therapeutic options for the virus.  The company is delighted to have received this support from Innovate UK and is proud to have earned one of the 800 grants awarded out of more than 8500 entries to the competition.”

Speaking about the scheme, Dr Ian Campbell, executive Chair of Innovate UK, said:

“Businesses from all over the UK have answered our call rapidly to meet the challenges we face today and in the future through the power of innovation.  The ideas we have seen can truly make a significant impact on society, improve the lives of individuals, especially those in vulnerable groups and enable businesses to prosper in challenging circumstances.”

Any enquiries concerning ProAxsis’ work with cytokines can be directed to info@proaxsis.com. 

ABOUT PROAXSIS

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated in to a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.

Aside from the provision of assays, ProAxsis is able to offer sample analysis at its purpose-built laboratory facility in Belfast, and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is one of the core portfolio companies of Netscientific plc.  The company is also supported by QUBIS, the commercialisation arm of the Queens University Belfast.

August 3, 2020

Related News

Other posts that you should not miss.
Announcements, News

ProAxsis appoints experienced Sales and Marketing Manager

April 20, 2016
-
Posted by Webmaster

ProAxsis is pleased to announce the appointment of Sarah Ganniclefft to the newly created role of Sales …

Read More
April 20, 2016
Posted by Webmaster
News

ProAxsis releases new NEATstik® data at the Irish Thoracic Society Conference 2021

November 15, 2021
-
Posted by Jessica Robinson

Dr Darragh McCafferty, ProAxsis’ Head of Assay Development, will be presenting new data on the company’s ongoing …

Read More
November 15, 2021
Posted by Jessica Robinson
Announcements, News, Trials

ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

June 19, 2017
-
Posted by Webmaster

ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the …

Read More
June 19, 2017
Posted by Webmaster
← PREVIOUS POST
NetScientific acquires 100% control of portfolio company ProAxsis Limited
NEXT POST →
ProAxsis investing in R&D to create new diagnostic tests for chronic human diseases
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • July 26, 2022
    ProAxsis announces additional key appointments
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis accelerates work on inflammatory biomarkers associated with COVID-19 - ProAxsis